RITLECITINIB

Other

Brand names: Litfulo

Oral

Mechanism of Action

12.1 Mechanism of Action LITFULO is a kinase inhibitor. Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib inhibits cytokine induced STAT phosphorylation mediated by JAK3-dependent receptors. Additionally, ritlecitinib inhibits signaling of immune receptors dependent on TEC kinase family members. The relevance of inhibition of specific JAK or TEC family enzymes to therapeutic effectiveness is not currently known.

Indications

biologic immunomodulators

cyclosporine or other potent immunosuppressants ( 1 ).

FDA Warnings

5 WARNINGS AND PRECAUTIONS • Hypersensitivity: Discontinue LITFULO if a clinically significant hypersensitivity reaction occurs
1 Serious Infections Serious infections have been reported in patients receiving LITFULO
The most frequent serious infections have been appendicitis, COVID-19 infection (including pneumonia), and sepsis [see Adverse Reactions (6
Avoid use of LITFULO in patients with an active, serious infection

Known Side Effects

9 documented side effects by frequency

Drug Not Working

>10%

Condition Worsened

1-10%

Headache

1-10%

Diarrhea

0.1-1%

Hair Loss

0.1-1%

Itching

0.1-1%

Fatigue

0.1-1%

Rash

0.1-1%

Nausea

0.1-1%

Community Discussions

No community discussions found for RITLECITINIB yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral